Eden Prairie, MN, Nov. 09, 2017 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCMARKETS: PETV) (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce that Mr. David Merrill has joined the Company’s Board of Directors.
Mr. Merrill is an accomplished Senior Executive in the Medical Device Industry. He is currently the CEO of the Merrill Family Enterprises, LLC (FME) which in different capacities gets directly involvedwith Medical Device companies.
: “I’m honored to join the PetVivo Holdings team. I evaluated the opportunity based upon the team’s leadership, fiscal responsibility, patent portfolio (existing and in process) and the science. Does the Science offer positive patient, medical professional and economic outcomes? PetVivo surpassed my expectations”
Mr. Merrill started his lengthy Medical Device career at Medtronic in 1973 selling implantable cardiac devices. After being inducted into the prestigious Medtronic’s President’s Club for his achievements, Merrill career expanded to District Manager then to Director, Sales Development, and Support in 1982. At that time, he moved to St. Jude Medical as Senior Director of their Southwest Region overseeing Direct and Independent sales representatives in 10 states. Roughly ten years from joining St. Jude he returned to Medtronic’s to be Vice President, Cardiac Rhythm Management, Asia-Pacific. He relocated to Hong Kong working internationally until his early retirement (30 Years) from Medtronic
After finding his retirement highly over rated he joined I-Flow as VP of International. During his time with I-Flow he negotiated distribution agreements throughout the UK, Scandinavia, Korea, Japan, Mexico, Brazil, Turkey, India, China etc., increased annual revenues and gross margins. The company was sold to Kimberly-Clark.In addition, Mr. Merrill has negotiated agreements with such medical giants as B. Braum, Fresenius-Kabi and Terumo.
“I first met David in High School some 50+ years ago in St. Paul, Minnesota. We lost track of each other from time to time, but reconnected a couple of months ago as we discussed an idea that David called me about regarding our product. One thing always leads to another. I am excited that after some 14,000,000 miles and at one time or another having worked in 53 countries David has decided to share his expertise in medical products and international distribution with PetVivo. In addition to the excitement, I know it will be fun having David around.” Stated Wes Hayne, PetVivo’s CEO.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.